{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:42:03Z","timestamp":1776235323179,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kawasaki disease (KD) is the leading cause of acquired heart disease in children under 5 years of age worldwide. Approximately 15%\u201320% of KD patients are resistant to intravenous immunoglobulin (IVIG), and these patients have a significantly higher risk of developing coronary artery aneurysms (CAAs), a severe complication leading to long-term cardiovascular morbidity. Cholestatic hepatitis is a rare manifestation of KD, which further increases the difficulty of clinical treatment. This study reports a case of IVIG-resistant KD complicated with cholestatic hepatitis treated with infliximab, and explores the clinical challenges in preventing CAA progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 2-year-old Han Chinese male presented with persistent fever as the initial symptom, followed by typical clinical manifestations of KD and cholestatic hepatitis. Initial treatment with high-dose IVIG (2\u2005g\/kg) combined with clopidogrel (1\u2005mg\/kg\/day) was ineffective. A second dose of IVIG (1\u2005g\/kg) combined with high-dose methylprednisolone pulse therapy also failed to control the disease. On the ninth day of illness, salvage therapy with the tumor necrosis factor-alpha (TNF-\u03b1) inhibitor infliximab (5\u2005mg\/kg) was administered, and the child's fever subsided rapidly within 24\u2005h. Subsequent laboratory examinations showed that inflammatory indicators [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] and liver function indicators [alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, total bile acids (TBA)] improved significantly. However, despite effective inflammation control, echocardiographic follow-up revealed progressive development of CAAs, eventually forming giant CAAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Infliximab can effectively suppress systemic inflammation and improve liver function in patients with IVIG-resistant KD complicated with cholestatic hepatitis. However, the development of giant CAAs in this case underscores the dissociation between systemic inflammation control and coronary protection, highlighting the critical importance of optimizing the timing of infliximab administration. Further randomized controlled trials are needed to clarify the optimal timing, dose, and patient selection criteria for infliximab in the treatment of IVIG-resistant KD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1794686","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:41:52Z","timestamp":1776231712000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Infliximab for intravenous immunoglobulin-resistant Kawasaki disease complicated with cholestatic hepatitis: a case report and discussion on coronary artery aneurysm prevention"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhong","family":"Yongxing","sequence":"first","affiliation":[{"name":"Shaoxing Maternal and Child Health Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Shaoxing Maternal and Child Health Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Qi","sequence":"additional","affiliation":[{"name":"Children's Hospital of Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Fangyan","sequence":"additional","affiliation":[{"name":"Shaoxing Maternal and Child Health Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals from the American Heart Association","volume":"135","author":"McCrindle","year":"2017","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.jacc.2015.12.073","article-title":"Kawasaki disease","volume":"67","author":"Newburger","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/MOP.0b013e32833e12f7","article-title":"Long-term prognosis of Kawasaki disease: increased cardiovascular risk?","volume":"22","author":"Fukazawa","year":"2010","journal-title":"Curr Opin Pediatr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41584-020-0426-0","article-title":"Kawasaki disease: pathophysiology and insights from mouse models","volume":"16","author":"Noval Rivas","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/1744666X.2017.1232165","article-title":"Kawasaki disease: etiopathogenesis and novel treatment strategies","volume":"13","author":"Agarwal","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3349\/ymj.2012.53.2.262","article-title":"Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a \u201cprotein homeostasis system\u201d","volume":"53","author":"Lee","year":"2012","journal-title":"Yonsei Med J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3345\/cep.2021.01270","article-title":"Etiological and pathophysiological enigmas of severe coronavirus disease 2019, multisystem inflammatory syndrome in children, and Kawasaki disease","volume":"65","author":"Rhim","year":"2022","journal-title":"Clin Exp Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2188\/jea.JE20110126","article-title":"Epidemiologic features of Kawasaki disease in Japan: results of the 2009\u20132010 nationwide survey","volume":"22","author":"Nakamura","year":"2012","journal-title":"J Epidemiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jinf.2016.04.015","article-title":"Adjunctive therapies for Kawasaki disease","volume":"72","author":"Campbell","year":"2016","journal-title":"J Infect"},{"key":"B10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s12016-016-8581-4","article-title":"Effect and safety of TNF inhibitors in immunoglobulin-resistant Kawasaki disease: a meta-analysis","volume":"52","author":"Xue","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1546-0096-7-3","article-title":"Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report","volume":"7","author":"Brogan","year":"2009","journal-title":"Pediatr Rheumatol Online J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1149519","DOI":"10.3389\/fped.2023.1149519","article-title":"Treatment of immunoglobulin-resistant kawasaki disease: a Bayesian network meta-analysis of different regimens","volume":"11","author":"Pan","year":"2023","journal-title":"Front Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4070\/kcj.2018.0214","article-title":"Infliximab treatment for intravenous immunoglobulin-resistant Kawasaki disease: a multicenter study in Korea","volume":"49","author":"Hur","year":"2019","journal-title":"Korean Circ J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s10067-017-3952-7","article-title":"Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients","volume":"37","author":"Hachiya","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","article-title":"Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease","volume":"153","author":"Burns","year":"2008","journal-title":"J Pediatr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.echo.2010.10.004","article-title":"New equations and a critical appraisal of coronary artery Z scores in healthy children","volume":"24","author":"Dallaire","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jpeds.2010.10.012","article-title":"Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study","volume":"158","author":"Son","year":"2011","journal-title":"J Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/15513818509026899","article-title":"Hepatomegaly and splenomegaly in Kawasaki disease","volume":"4","author":"Ohshio","year":"1985","journal-title":"Pediatr Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4070\/kcj.2010.40.7.334","article-title":"Infliximab treatment for refractory Kawasaki disease in Korean children","volume":"40","author":"Song","year":"2010","journal-title":"Korean Circ J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(13)62298-9","article-title":"Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"383","author":"Tremoulet","year":"2014","journal-title":"Lancet"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1794686\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:41:53Z","timestamp":1776231713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1794686\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":20,"alternative-id":["10.3389\/fped.2026.1794686"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1794686","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1794686"}}